Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify predictive and prognostic variables for overall survival (OS) in chemotherapy-naïve men with mCRPC treated with enzalutamide. Patients and methods: Patients from the PREVAIL trial database (enzalutamide versus placebo) were randomly split 2 : 1 into training (n = 1159) and testing (n = 550) sets. Using the training set, 23 predefined variables were analyzed and a multivariable model predicting OS was developed and validated in an independent testing set. Results: Patient characteristics and outcomes were well balanced between training and testing sets; median OS was 32.7 months in each. The final validated multivariable model included 11 independent prognostic variables. Median OS for low-, intermediate-, and high-risk groups (testing set) defined by prognostic risk tertiles were not yet reached (NYR) (95% CI NYR-NYR), 34.2 months (31.5-NYR), and 21.1 months (17.5-25.0), respectively. Hazard ratios (95% CI) for OS in the low- and intermediate-risk groups versus high-risk group were 0.20 (0.14-0.29) and 0.40 (0.30-0.53), respectively. Secondary outcomes of response and progression differed widely in model-defined risk groups. Enzalutamide improved outcomes in all prognostic risk groups. Conclusions: Our validated prognostic model incorporates variables routinely collected in chemotherapy-naïve men with mCRPC treated with enzalutamide, identifying subsets of patients with widely differing survival outcomes that provide useful information for external validation, patient care, and clinical trial design. Trial registration: ClinicalTrials.gov: NCT01212991.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to visceral metastases, multiple clinical factors have demonstrated an association with varying prognoses, including PSA, alkaline phosphatase, hemoglobin, albumin, and lactate dehydrogenase [48–50].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationTempleton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Self-citationAbiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Self-citationAR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Research works printed but not linked: 1
- 1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, 2016. http://globocan.iarc.fr (31 May 2018, date last accessed).
Cited by
Armstrong, A. J., Lin, P., Tombal, B., Saad, F., Higano, C. S., Joshua, A. M., Parli, T., Rosbrook, B., van Os, S., & Beer, T. M. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.061 · Cited by 168
Self-citationAndrogen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
Jacob, A., Raj, R., Allison, D. B., & Myint, Z. W. (2021) · Cancers · doi:10.3390/cancers13215417 · Cited by 160
“These failures can be partly attributed to AR variants (19-21).”
BackgroundFonseca, N. M., Maurice-Dror, C., Herberts, C., Tu, W., Fan, W., Murtha, A. J., Kollmannsberger, C., Kwan, E. M., Parekh, K., Schönlau, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45475-w · Cited by 145
Guan, Y., Xiong, H., Feng, Y., Liao, G., Tong, T., & Pang, J. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0209-3 · Cited by 90
Gebrael, G., Sahu, K. K., Chigarira, B., Tripathi, N., Mathew Thomas, V., Sayegh, N., Maughan, B. L., Agarwal, N., Swami, U., & Li, H. (2023) · Cancers · doi:10.3390/cancers15143717 · Cited by 85
“For instance, deep learning algorithms have been employed to predict overall survival in patients with metastatic castration-resistant prostate cancer [10].”
BackgroundAnnala, M., Fu, S., Bacon, J. V. W., Sipola, J., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S. J., Lo, G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.205 · Cited by 73
Jayaram, A., Wingate, A., Wetterskog, D., Wheeler, G., Sternberg, C. N., Jones, R. J., Berruti, A., Lefresne, F., Lahaye, M., Thomas, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.196 · Cited by 68
Self-citationSperger, J. M., Emamekhoo, H., McKay, R. R., Stahlfeld, C. N., Singh, A., Chen, X. E., Kwak, L., Gilsdorf, C. S., Wolfe, S. K., Wei, X. X., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00169 · Cited by 68
“However, approximately 5%-10% of patients will have primary resistance to ARSI treatment and a majority of initial responders will develop resistance within 1-3 years.(6-8) The underlying drivers of treatment resistance can include activating AR genomic alterations (amplifications, mutations, and rearrangements), epig…”
BackgroundSelf-citationTolmeijer, S. H., Boerrigter, E., Sumiyoshi, T., Kwan, E. M., Ng, S. W. S., Annala, M., Donnellan, G., Herberts, C., Benoist, G. E., Hamberg, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2998 · Cited by 66
Fong, L. H., Morris, M. J., Sartor, O. A., Higano, C. S., Pagliaro, L. C., Alva, A. S., Appleman, L. J., Tan, W. W., Vaishampayan, U. N., Porcu, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0063 · Cited by 63
Self-citationChang, H., Chen, S.-Y., Wu, C., Lu, C., & Yen, G. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b00251 · Cited by 56
Emmett, L., Subramaniam, S., Joshua, A. M., Crumbaker, M., Martin, A. J., Zhang, A. Y., Rana, N., Langford, A., Mitchell, J., Yip, S., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15491 · Cited by 50
Benoist, G. E., van Oort, I. M., Boerrigter, E., Verhaegh, G. W. C. T., van Hooij, O., Groen, L., Smit, F. P., de Mol, P., Hamberg, P., Dezentjé, V. O., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa095 · Cited by 42
Kwan, E. M., Wyatt, A. W., & Chi, K. N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1054497 · Cited by 44
Armstrong, A. J., Lin, P., Higano, C. S., Iversen, P., Sternberg, C. N., TOMBAL, B. F., Phung, D., Parli, T., Krivoshik, A., & Beer, T. M. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.11.005 · Cited by 41
Self-citationJayaram, A., Wingate, A., Wetterskog, D., Conteduca, V., Khalaf, D. J., Sharabiani, M. T. A., Calabrò, F., Barwell, L., Feyerabend, S., Grande, E., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00123 · Cited by 37
Self-citationMcManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00906-z · Cited by 32
“Several multivariable models are available that incorporate these factors to help inform prognoses for patients with mCRPC [48 – 50], and prognostic knowledge from these models may inform treatment decision-making.”
Self-citationHalabi, S., Yang, Q., Roy, A., Luo, B., Araujo, J. C., Logothetis, C., Sternberg, C. N., Armstrong, A. J., Carducci, M. A., Chi, K. N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02661 · Cited by 30
“We know that PSA, ALP, LDH, and hemoglobin are biomarkers that measure AR activity, bone osteoblastic activity/burden, tumor necrosis, metabolism, and bonemarrow infiltration.(10,27-36) Measures of host response, including neutrophil-to-lymphocyte ratio, albumin, pain, and patterns of spread on imaging, are key factor…”
BackgroundSelf-citationLoubersac, T., Nguilé-Makao, M., Pouliot, F., Fradet, V., & Toren, P. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.01.009 · Cited by 27
Sternberg, C. N. (2019) · Future Oncology · doi:10.2217/fon-2018-0940 · Cited by 27
Self-citationFischer, S., Clements, S., McWilliam, A., Green, A., Descamps, T., Oing, C., & Gillessen, S. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100256 · Cited by 26
de Wit, R., Wülfing, C., Castellano, D., Kramer, G., Eymard, J. C., Sternberg, C. N., Fizazi, K. S., TOMBAL, B. F., Bamias, A., Carles, J., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100241 · Cited by 26
“5) was identified as a novel independent prognostic factor in the minimally symptomatic mCRPC setting by a validated model developed using the phase III PREVAIL database.(29) As the PREVAIL study evaluated the efficacy and safety of enzalutamide versus placebo in chemotherapy-naive patients with mCRPC, this model refl…”
MethodSelf-citationFrom biology to the clinic — exploring liver metastasis in prostate cancer
Ni, X., Yu, W., Li, X., Pan, J., Fang, B., Zhang, T., Lu, Y., Ye, D., & Zhu, Y. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00875-x · Cited by 25
“…parameters such as age, PSA doubling time, Gleason Score, simple node metastasis, primary treatment and time from CRPC to metastasis showed an area under the curve (AUC) of 0.45 when considering all these conventional parameters, indicating no better predictive power than random chance 130 .”
InfluentialMiyazawa, Y., Sekine, Y., Shimizu, N., Takezawa, Y., Nakamura, T., Miyao, T., Nakayama, H., Kurihara, S., Syuto, T., Nomura, M., et al. (2019) · The Prostate · doi:10.1002/pros.23865 · Cited by 24
“They used a nomogram to determine 11 prognostic factors based on estimated regression coefficients from the final multivariable Cox proportional hazards model of OS of the PREVAIL study.(26) Notably, the time period before initiation of ENZ therapy and Hb were both included among their 11 risk factors, similar to our…”
Conteduca, V., Scarpi, E., Caroli, P., Lolli, C., Gurioli, G., Brighi, N., Poti, G., Farolfi, A., Altavilla, A., Schepisi, G., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13120 · Cited by 21
George, D. J., Agarwal, N., Sartor, O. A., Sternberg, C. N., TOMBAL, B. F., Saad, F., Miller, K., Constantinovici, N., Guo, H., Reeves, J. A., et al. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00488-0 · Cited by 20
Self-citationGupta, S., To, T. M., Graf, R. P., Kadel, E. E., Reilly, N. R., & Albarmawi, H. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00562 · Cited by 18
Takemura, K. N., Ito, M., Nakanishi, Y., Kataoka, M., Sakamoto, K., SUZUKI, H., Tobisu, K., & Koga, F. (2019) · Anticancer Research · doi:10.21873/anticanres.13780 · Cited by 18
Fernández-Pérez, M. P., Pérez, E., Alonso‐Gordoa, T., Conteduca, V., Pous, A. F., Vázquez‐Estévez, S., del Alba, A. G., Wetterskog, D., Antonarakis, E. S., Mellado, B., et al. (2022) · The Prostate · doi:10.1002/pros.24469 · Cited by 17
“Clinical prognostic models in mCRPC, including a prognostic model in patients treated with enzalutamide in first ‐ line mCRPC 24 are intended to deal with this heterogeneity.”
MethodHalabi, S., Guo, S., Luo, B., Yu, C., Knutson, T. P., Kobilka, A., Lyman, J., Beltran, H., Antonarakis, E. S., Galsky, M. D., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.07.011 · Cited by 16
Self-citationMaurice Dror, C., Chi, K. N., & Khalaf, D. J. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1341 · Cited by 14
Salidroside suppresses proliferation and migration in prostate cancer via the PI3K/AKT pathway
Liu, R.-H., Ma, T.-F., Yang, Q., Xiao, W.-C., Yin, L., Yin, M., Zhang, J.-S., & Wang, C.-H. (2023) · Cancer Biomarkers · doi:10.3233/cbm-220454 · Cited by 14
“Many advanced prostate cancers initially respond to androgen ablation therapy, but then develop an aggressive androgen-independent phenotype that is resistant to conventional therapy and metastases to lymph nodes and bone [24–26].”
Domingo, J. J. S., Alonso‐Gordoa, T., Álvaro, J. L., Molina‐Cerrillo, J., Barquín, A., Martínez‐Sáez, O., Revilla, J. B., Carrato, A., & Rodríguez, S. Á. (2021) · Therapeutic Advances in Urology · doi:10.1177/17562872211043341 · Cited by 13
Liu, Y.-M., Wu, A., Chen, Y., Ma, T., Dong, B., She, Z., Yi, M., & Mao, W.-M. (2023) · Medical Oncology · doi:10.1007/s12032-023-02254-9 · Cited by 13
“Many advanced prostate cancers initially respond to androgen ablative therapy, but later develop an aggressive androgen non-dependent phenotype that is resistant to conventional therapy and metastasizes to lymph nodes and bone [9–11].”
The prognostic value of pain in castration-sensitive prostate cancer
Iacovelli, R., Ciccarese, C., Caffo, O., Giorgi, U. D., Tucci, M., Mosillo, C., Bimbatti, D., Pierantoni, F., Maines, F., Casadei, C., et al. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0255-x · Cited by 12
Lorente, D., Llácer, C., Lozano, R., de Velasco, G., Romero-Laorden, N., Rodrigo-Aliaga, M., Sánchez-Iglesias, Á. L., di Capua, C., Castro, E., Albiach, C. F., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.07.014 · Cited by 11
Aydın, S. G., Kutlu, Y., Muğlu, H., Aydın, A., Açıkgöz, Ö., Hamdard, J., Karcı, E., Bilici, A. E., Ölmez, Ö. F., & Yıldız, Ö. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04592-x · Cited by 11
Gebrael, G., Jo, Y., Swami, U., Plets, M., Chehade, C. H., Narang, A., Gupta, S., Myint, Z. W., Sayegh, N., Tangen, C. M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.19966 · Cited by 11
Roy, S., Morgan, S. C., Wallis, C. J. D., Sun, Y., Spratt, D. E., Malone, J., Grimes, S., Mukherjee, D., Kishan, A. U., Saad, F., et al. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00529-2 · Cited by 10
Ni, X., Wang, Z., Li, X., Sui, J., Ma, W., Pan, J., Ye, D., & Zhu, Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002321 · Cited by 10
“…to the lack of well-established prognostic models for nmCRPC patients, high-quality clinical multivariable prognostic models have been established for metastatic castration-resistant prostate cancer (mCRPC) patients, both for chemotherapy-naïve mCRPC and post-chemotherapy mCRPC [ 9 , 10 ] .”
InfluentialFreedland, S. J., Li, S. L., Pilon, D., Bhak, R. H., Narkhede, S., Lefèbvre, P., & Young‐Xu, Y. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1888704 · Cited by 10
Boerrigter, E., Benoist, G. E., van Oort, I. M., Verhaegh, G. W. C. T., de Haan, A. F. J., van Hooij, O., Groen, L., Smit, F. P., Oving, I. M., de Mol, P., et al. (2021) · Cancers · doi:10.3390/cancers13246279 · Cited by 9
Ying, Y., Liu, Q., Li, X., Zhang, H., Xu, X., Ma, Q., Nowsheen, S., Aziz, K., Li, Y., Lou, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw7989 · Cited by 8
Aparicio, A. M., Tidwell, R. S. S., Yadav, S. S., Chen, J., Zhang, M., Liu, J., Guo, S., Pilie, P. G., Yu, Y., Song, X., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3740 · Cited by 8
Nakamura, S., Nagata, M., Nagaya, N., Ashizawa, T., Hirano, H., Lü, Y., Ide, H., & Horie, S. (2024) · Cancers · doi:10.3390/cancers16040772 · Cited by 8
Kwon, D. H.-M., Zhang, L., Quigley, D. A., Foye, A., Chen, W. S., Wong, C. K., Feng, F. Y.-C., Bailey, A. M., Huang, J., Stuart, J. M., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.06.002 · Cited by 8
Self-citationStefano, R. F. D., Tucci, M., Turco, F., Samuelly, A., Bungaro, M., Pisano, C., Vignani, F., Gallicchio, M., Scagliotti, G. V., Maïo, M. D., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00336-1 · Cited by 7
Castro, E., Wang, D., Walsh, S., Craigie, S., Haltner, A., Nazari, J. L., Niyazov, A., & Samjoo, I. A. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00924-x · Cited by 6
“Factors predictiveof the treatment effect of therapies inmCRPC were identi fi ed through the literature [20] and clinical expertise and were ranked in order of importance by an experienced clinician (see Supplementary Table 2).”
Chen, H., de Kouchkovsky, I., Bok, R., Ohliger, M. A., Wang, Z. J., Gebrezgiabhier, D., Nickles, T. M., Carvajal, L. E., Gordon, J. W., Larson, P. E. Z., et al. (2025) · Cancers · doi:10.3390/cancers17132211 · Cited by 5
“While k PL,median and k PL,max were significantly associated with both PFS and OS, the same association was not found in this study for established serological prognostic markers such as PSA, LDH, and ALP [44,45].”
Zhang, X.-Q., Huang, Z., Ju, W., Zheng, C.-Y., Liu, X.-D., Huang, Y., Chen, Q., Li, P., Xie, J., Zheng, C., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13545-x · Cited by 5
Fukuokaya, W., Kimura, T., Urabe, F., Kimura, S., Tashiro, K., Tsuzuki, S., Koike, Y., Sasaki, H., Miki, K., & Egawa, S. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01712-y · Cited by 5
“Other factors identified in this study have well been recognized in predicting overall survival in mCRPC [4, 5].”
BackgroundBadve, S., Cho, S., Lu, X., Cao, S., Ghose, S., Thike, A. A., Tan, P. H., Ocal, I. T., Generali, D., Zanconati, F., et al. (2022) · Cancers · doi:10.3390/cancers14163916 · Cited by 5
Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy
Hu, B., Shu, F., Liu, Y., Zhu, J., Wang, H., Xie, N., Liu, X., Jiang, G., Yan, M., & Dai, Y. (2023) · Journal of Cancer · doi:10.7150/jca.81513 · Cited by 5
Developing prognostic models for advanced prostate cancer when the goal line keeps changing
Fu, S. Y. F., & Chi, K. N. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy419 · Cited by 4
Sasaki, T., Takahashi, T., Sekito, S., Kanda, H., Higashi, S., Masui, S., Kojima, T., Matsuura, H., Nishikawa, K., Akamatsu, S., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.05.015 · Cited by 4
Caram, M. E. V., Kumbier, K. E., Tsao, P. A., Burns, J., Sparks, J. B., Stensland, K. D., Reichert, Z. R., Alumkal, J. J., Hollenbeck, B. K., Shahinian, V. B., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7334 · Cited by 4
Farinea, G., Cozzone, L., Butticè, S., Mogavero, A., Stefano, R. F. D., Angusti, T., Parente, A., Tucci, M., & Buttigliero, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104819 · Cited by 3
Halabi, S., Luo, B., Yu, C., Rydzewska, L. H. M., Roy, A., Kim, H., Godolphin, P. J., Murphy, L. R., Carducci, M. A., Gravis, G., et al. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.02.001 · Cited by 2
Romero, M. E. J., Gallego, M. C., Serrato, J. C., Hurtado, M. A. S., & Santotoribio, J. D. (2021) · Anticancer Research · doi:10.21873/anticanres.15192 · Cited by 2
New research in prostate cancer, ASCO-GU 2017
Chi, K., & Fred Saad, C. (2017) · Canadian Urological Association Journal · doi:10.5489/cuaj.4608 · Cited by 2
Castro, E., Wang, D., Walsh, S., Craigie, S., Haltner, A., Nazari, J. L., Niyazov, A., & Samjoo, I. A. (2025) · Future Oncology · doi:10.1080/14796694.2025.2471200 · Cited by 1
“Identified factors from the literature [22] and clinical expertise were ranked in order of importance by an experienced clinician based on their anticipated impact on the outcome; all available factors were used for the primary analysis.”
Brighi, N., Schepisi, G., Conteduca, V., Scarpi, E., Caroli, P., Matteucci, F., & Lolli, C. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s509285 · Cited by 1
Khan, A. A., Nema, P., Kashaw, V., & Kashaw, S. K. (2025) · Talanta · doi:10.1016/j.talanta.2025.129132 · Cited by 1
Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival
Büttner, T., Klümper, N., Ellinger, J., Ritter, M., & Krausewitz, P. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0300 · Cited by 1
Özmen, A., Kapar, C., Gültürk, İ., Şahin, S., Şeker, K. G., Tuğcu, V., & Tural, D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103968 · Cited by 1
“…prostate cancer (mCRPC), including bone pain, Eastern Cooperative Oncology Group (ECOG) performance status (PS), Gleason score, hemoglobin (Hb) level, prostate-specific antigen (PSA) level, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and the presence of visceral disease [3,4].”
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
Ognerubov, N. A. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.3.201201 · Cited by 1
Elumalai, T., Barker, C., Elliott, T., Malik, J., Tran, A. T. H., Hudson, A., Song, Y. P., Patel, K., Lyons, J., Hoskin, P., et al. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.01.040 · Cited by 1
Caffo, O., Basso, U., Cattrini, C., Ermacora, P., Maruzzo, M., Alberti, M., Anesi, C., Bimbatti, D., Cani, M., Crespi, V., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102265
“13 More recently 2 prognostic models were developed in populations enrolled in PREVAIL trial 14 and COU-AA-301 trial.”
Veccia, A., Basso, U., Cattrini, C., Ermacora, P., Maruzzo, M., Alberti, M., Anesi, C., Bimbatti, D., Cani, M., Crespi, V., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2497749
Lorente Estellés, D. (2020) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
中村, 聡. (2022) · Institutional Repositories DataBase (IRDB)
Circulating tumor DNA measurements to refine cancer treatment
Tolmeijer, S. H. (2023) · Radboud Repository (Radboud University)
Montiel-Jarquín, Á. J., García-Galicia, A., Cerrillo, J. G. N., Bertado-Ramírez, N. R., & Vargas-Vargas, V. M. (2026) · Anales Médicos de la Asociación Médica del Centro Médico ABC · doi:10.24875/amh.m26000145
CDA-AMC (2026) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2026.1397
Najdawi, F., Sayyid, R. K., Ahlering, T. E., Lee, D. I., Dobbs, R. W., & Shahait, M. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01776-5
Castro, E., Wang, D., Paganelli, S., Haltner, A., Su, N., Kirker, M., Chang, J., & Samjoo, I. A. (2026) · The Oncologist · doi:10.1093/oncolo/oyag143
Tohumcuoğlu, M., Köşeci, T., Duşgün, A., Yetişir, A. E., Mirili, C., Mete, B., & Büyükşimşek, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124816
“…models reported by Halabi et al., Chi et al., and Armstrong et al. identified variables such as performance status, hemoglobin, alkaline phosphatase, lactate dehydrogenase, PSA-related parameters, metastatic distribution, and treatment history as important determinants of survival in mCRPC [13–15].”
吴振启, Wu, Z., Liu, Y., & Adhikari, K. (2026) · Research Square · doi:10.21203/rs.3.rs-9253172/v1
Uccello, M., Vlachostergios, P. J., Ghose, A., & Boussios, S. (2026) · Cancers · doi:10.3390/cancers18162660
“This may limit their use as simple, transparent risk classifications across heterogeneous clinical-trial and real-world datasets [1,2,8].”
External Risk Prediction Informed Bayesian Survival AnalysisPreprint
Jeon, Y., Huang, Y., Kim, H. J., Halabi, S., & Kim, M. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2608.28887
Hansen, E. B., Antonsen, K. W., Jochumsen, M. R., Salachan, P. V., Bouchelouche, K., Hansen, T. F., Osther, P. J. S., Zedan, A. H., Borre, M., Møller, H. J., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03633-5
Lorente, D., Tello-Velasco, D., Ovejero-Sánchez, M., Jambrina, A., Romero-Laorden, N., Gonzalez-Ginel, I., Miguel-Masia, J., Lozano, R., de Velasco, G., Nunes‐Carneiro, D., et al. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.09.018
Metadata
- Authors
- Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., Krivoshik, A., & Beer, T. M.
- Affiliations
- Duke University (US)
- Pfizer (United States) (US)
- University of Washington (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- University of Alabama at Birmingham (US)
- Cliniques Universitaires Saint-Luc (BE)
- University of Basel (CH)
- Université Paris-Sud (FR)
- Astellas Pharma (Netherlands) (NL)
- Astellas Pharma (United States) (US)
- Oregon Health & Science University (US)
- Corresponding author
- Armstrong, A.J.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 29
- Issue
- 11
- Pages
- 2200-2207
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC6888025
- OpenAlex
- W2892249349
- Cited by
- 71
- References
- 31
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 16 · 2020: 7 · 2019: 6 · 2018: 2
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Funders
- Astellas Pharma, Inc
- Duke Cancer Center's P30 (CA014236)
- US Department of Defense Prostate Cancer Clinical Trials Consortium
- DOD
- PCCTC (W81XWH-14-2-0179)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- metastatic castration-resistant prostate cancer, enzalutamide, prognostic model, overall survival, chemotherapy-naive patients, PREVAIL trial, risk stratification, androgen receptor antagonists, external validation
- MeSH terms
- Progression-Free Survival, Aged, Androgen Antagonists, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Male, Models, Biological, Nitriles, Phenylthiohydantoin, Prognosis, Biomarkers, Tumor, Proportional Hazards Models, Disease Progression, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.